Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Francesca Blasco

Showing results (21-30 of 28) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 28 results.
Molecular Cancer Therapeutics|July 1, 2010
Potent and selective inhibition of polycythemia by the quinoxaline JAK2 inhibitor NVP-BSK805Fabienne Baffert, Catherine H Régnier, Alain De Pover, et al.
Journal of Virology|May 29, 2015
Discovery of Dengue Virus NS4B InhibitorsQing-Yin Wang, Hongping Dong, Bin Zou, et al.
ACS Medicinal Chemistry Letters|April 17, 2015
Lead optimization of spiropyrazolopyridones: a new and potent class of dengue virus inhibitorsBin Zou, Wai Ling Chan, Mei Ding, et al.
Antimicrobial Agents and Chemotherapy|September 22, 2020
A Cyclic Phosphoramidate Prodrug of 2'-Deoxy-2'-Fluoro-2'-<i>C</i>-Methylguanosine for the Treatment of Dengue Virus InfectionRatna Karuna, Fumiaki Yokokawa, Keshi Wang, et al.
Science Translational Medicine|January 9, 2015
Direct inhibitors of InhA are active against Mycobacterium tuberculosisUjjini H Manjunatha, Srinivasa P S Rao, Ravinder Reddy Kondreddi, et al.
Nature|June 1, 2017
A Cryptosporidium PI(4)K inhibitor is a drug candidate for cryptosporidiosisUjjini H Manjunatha, Sumiti Vinayak, Jennifer A Zambriski, et al.
Science Translational Medicine|December 6, 2013
Indolcarboxamide is a preclinical candidate for treating multidrug-resistant tuberculosisSrinivasa P S Rao, Suresh B Lakshminarayana, Ravinder R Kondreddi, et al.
Science Translational Medicine|February 4, 2021
NITD-688, a pan-serotype inhibitor of the dengue virus NS4B protein, shows favorable pharmacokinetics and efficacy in preclinical animal modelsStephanie A Moquin, Oliver Simon, Ratna Karuna, et al.
Pageof 3

Showing results (21-30 of 28) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 28 results.
Molecular Cancer Therapeutics|July 1, 2010
Potent and selective inhibition of polycythemia by the quinoxaline JAK2 inhibitor NVP-BSK805Fabienne Baffert, Catherine H Régnier, Alain De Pover, et al.
Journal of Virology|May 29, 2015
Discovery of Dengue Virus NS4B InhibitorsQing-Yin Wang, Hongping Dong, Bin Zou, et al.
ACS Medicinal Chemistry Letters|April 17, 2015
Lead optimization of spiropyrazolopyridones: a new and potent class of dengue virus inhibitorsBin Zou, Wai Ling Chan, Mei Ding, et al.
Antimicrobial Agents and Chemotherapy|September 22, 2020
A Cyclic Phosphoramidate Prodrug of 2'-Deoxy-2'-Fluoro-2'-<i>C</i>-Methylguanosine for the Treatment of Dengue Virus InfectionRatna Karuna, Fumiaki Yokokawa, Keshi Wang, et al.
Science Translational Medicine|January 9, 2015
Direct inhibitors of InhA are active against Mycobacterium tuberculosisUjjini H Manjunatha, Srinivasa P S Rao, Ravinder Reddy Kondreddi, et al.
Nature|June 1, 2017
A Cryptosporidium PI(4)K inhibitor is a drug candidate for cryptosporidiosisUjjini H Manjunatha, Sumiti Vinayak, Jennifer A Zambriski, et al.
Science Translational Medicine|December 6, 2013
Indolcarboxamide is a preclinical candidate for treating multidrug-resistant tuberculosisSrinivasa P S Rao, Suresh B Lakshminarayana, Ravinder R Kondreddi, et al.
Science Translational Medicine|February 4, 2021
NITD-688, a pan-serotype inhibitor of the dengue virus NS4B protein, shows favorable pharmacokinetics and efficacy in preclinical animal modelsStephanie A Moquin, Oliver Simon, Ratna Karuna, et al.
Pageof 3